Synthesis and structure–activity relationship studies in serotonin 5-HT4 receptor ligands based on a benzo[de][2,6]naphthridine scaffold
摘要:
A small series of serotonin 5-HT4 receptor ligands has been designed from flexible 2-methoxyquinoline compounds 7a,b by applying the conformational constraint approach. Ligands 7a,b and the corresponding conformationally constrained analogues 8a-g were synthesized and their interactions with the 5-HT4 receptor were examined by measuring both binding affinity and the ability to promote or inhibit receptor-G protein coupling. Ester derivative 7a and conformationally constrained compound 8b were demonstrated to be the most interesting compounds showing a nanomolar 5-HT4R affinity similar to that shown by reference ligands cisapride (1) and RS-23,597-190 (4). The result was rationalized by docking studies in term of high similarity in the binding modalities of flexible 7a and conformationally constrained 8b. The intrinsic efficacy of some selected ligands was determined by evaluating the receptor-G protein coupling and the results obtained demonstrated that the nature and the position of substituents play a critical role in the interaction of these ligands with their receptor. (C) 2014 Elsevier Masson SAS. All rights reserved.
Counter-Current chromatography separation of isatin derivatives using the sandmeyer methodology
作者:Márcia R. Almeida、Gilda G. Leitão、Bárbara V. Silva、Jussara P. Barbosa、Angelo C. Pinto
DOI:10.1590/s0103-50532010000400025
日期:——
method, using high-speed counter-current chromatography (HSCCC) technique, was developed for the separation of isomericisatin derivatives, prepared following the Sandmeyer route. The biphasic solvent system composed of hexane:ethyl acetate:ethanol:water 1:0.5:0.5:1 (v/v/v/v) was used for all separations.
开发了一种快速高效的方法,使用高速逆流色谱(HSCCC)技术分离按照Sandmeyer路线制备的同分异构的Isatin衍生物。所有分离均使用由己烷:乙酸乙酯:乙醇:水1:0.5:0.5:1(v / v / v / v)组成的双相溶剂系统。
Synthesis and Biological Evaluation of Quinoline Salicylic Acids As P-Selectin Antagonists
作者:Neelu Kaila、Kristin Janz、Silvano DeBernardo、Patricia W. Bedard、Raymond T. Camphausen、Steve Tam、Desirée H. H. Tsao、James C. Keith、Cheryl Nickerson-Nutter、Adam Shilling、Ruth Young-Sciame、Qin Wang
DOI:10.1021/jm0602256
日期:2007.1.1
junctions into the underlying tissue. The initial rolling step is mediated by the interaction of leukocyte glycoproteins containing active moieties such as sialylLewisx (sLex) with P-selectin expressed on endothelial cells. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of inflammatory diseases such as arthritis
Extended Structure–Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)
作者:Koen Jansen、Leen Heirbaut、Robert Verkerk、Jonathan D. Cheng、Jurgen Joossens、Paul Cos、Louis Maes、Anne-Marie Lambeir、Ingrid De Meester、Koen Augustyns、Pieter Van der Veken
DOI:10.1021/jm500031w
日期:2014.4.10
(2S)-cyanoPro scaffold as a possible entry to highly potent and selective FAP inhibitors. In the present study, we explore in detail the structure–activityrelationship around this core scaffold. We report extensively optimized compounds that display low nanomolar inhibitory potency and high selectivity against the related dipeptidylpeptidases (DPPs) DPPIV, DPP9, DPPII, and prolyl oligopeptidase (PREP)
these transporters should not be addressed by such an inhibitor. A high-throughput screen against a library of ∼3 million compounds was performed to find a small molecule with this challenging potency and selectivity profile. The N-(1H-pyrazol-4-yl)quinoline-4-carboxamides were identified as an excellent starting point for further compound optimization. After extensive structure-activity relationship explorations
The present teachings relate to novel compounds of formula I:
wherein the constituent variables are as defined herein. Compounds of the present teachings can act as antagonists of the mammalian adhesion proteins known as selecting. Methods for treating or preventing selectin-mediated disorders are provided, which include administration of these compounds in a therapeutically effective amount.